Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in miceOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether orally administered neohesperidin, a natural flavonoid found in citrus fruits, could protect against neurodegeneration in a mouse model of Parkinson's disease. The model was induced using the neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Researchers assessed motor function, neural damage, colonic inflammation, and gut microbial composition, along with molecular signaling pathways underlying neuroinflammation.
Who was studied?
The subjects were mice injected with MPTP to induce Parkinson's disease-like pathology. The abstract does not specify the exact number of animals, strain, sex, or age used in the experiments. This was an animal model study rather than a human cohort.
What were the most important findings?
Neohesperidin administration improved motor impairment and reduced neural damage caused by MPTP injection. It also reduced colonic inflammation and tissue damage while regulating gut microbial imbalance in these mice. Mechanistically, neohesperidin suppressed the MPTP-induced inflammatory response by inhibiting excessive activation of the NF-kB and MAPK signaling pathways.
What are the greatest implications of this study?
These findings suggest that neohesperidin may attenuate Parkinson's disease-related neurodegeneration by simultaneously targeting neuroinflammation and gut microbial composition. This supports the broader concept that gut microbial regulation and anti-inflammatory pathways are linked in Parkinson's disease pathogenesis. The authors propose this provides a scientific basis for exploring neohesperidin as a potential treatment for Parkinson's disease and related conditions.